The-Unstoppable-CAR-T-Therapy | Esco VacciXcell
FDA Introductory Remarks Tisagenlecleucel Novartis Pharmaceuticals Corporation
A New Approach to Treat Childhood Leukemia: Novartis' CAR-T Therapy - Frazer A. Tessema, Jonathan J. Darrow, 2017
BLA 125646 Tisagenlecleucel 1 FDA Briefing Document Oncologic Drugs Advisory Committee Meeting BLA 125646 Tisagenlecleucel Novar
Frontiers | Chimeric Antigen Receptor, Teamwork, Education, Assessment, and Management (CAR-TEAM): A Simulation-Based Inter-professional Education (IPE) Intervention for Management of CAR Toxicities
FDA Advisory Committee Recommends Approval of CAR-T Cell Therapy and Two New Biosimilars | Biosimilars Law Bulletin
Non-viral precision T cell receptor replacement for personalized cell therapy | Nature
Manufacturing News of Note—New cell therapy facility in China | Fierce Pharma
Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell | Nature Medicine
Post-infusion CAR TReg cells identify patients resistant to CD19-CAR therapy | Nature Medicine
Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas | Nature Medicine
Mesoblast faces FDA pushback over cell therapy manufacturing, clinical data: documents | Fierce Pharma
Tumor response and endogenous immune reactivity after administration of HER2 CAR T cells in a child with metastatic rhabdomyosarcoma | Nature Communications
FDA Advisory Committee Recommends Approval of CAR-T Cell Therapy and Two New Biosimilars | Biosimilars Law Bulletin
With 2-pronged filing, Novartis' CAR-T med Kymriah aims to jump into Europe with both feet | Fierce Pharma
BLA 125646 Tisagenlecleucel 1 FDA Briefing Document Oncologic Drugs Advisory Committee Meeting BLA 125646 Tisagenlecleucel Novar
Current state of U.S. Food and Drug Administration regulation for cellular and gene therapy products: potential cures on the horizon - Cytotherapy
Fred Hutch Statement Regarding FDA Briefing About CAR T-cell Therapy
Optimizing CAR-T Cell Manufacturing Processes during Pivotal Clinical Trials - ScienceDirect
Allogeneic BCMA-targeting CAR T cells in relapsed/refractory multiple myeloma: phase 1 UNIVERSAL trial interim results | Nature Medicine
Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy | Nature Reviews Clinical Oncology
Novartis says it is ready to meet even 'unprecedented' demand for Zolgensma | Fierce Pharma
